Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 20/11/20 at 11:37am

The top ten news stories this week centre around coronavirus vaccine clinical trial results, as Pfizer and BioNTech have backed up their promising interim Phase 3 data showing 90% efficacy for their COVID-19 vaccine candidate with a final analysis of the findings, showing an even higher level of efficacy, and in crucial sub-populations.

In other news, the antidepressant fluvoxamine could treat COVID-19 patients and stop their symptoms from worsening, according to a new study, while AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19.

1. AstraZeneca’s Calquence fails to improve survival rates in coronavirus patients

AstraZeneca’s Calquence has failed to improve survival rates and prevent lung failure in patients hospitalised with COVID-19.

2. Pfizer launches pilot delivery programme for its coronavirus vaccine

Pfizer is set to launch its first delivery programme for the COVID-19 vaccine it developed with BioNTech. It will be located in multiple sites across America; the company said it has selected New Mexico, Tennessee, Rhode Island and Texas for the programme because of their differences in size and immunisation infrastructure.

3. Mylan and Upjohn merger will create a new entity: Viatris

The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has been revealed. The new entity will be known as Viatris, a name derived from Latin which is designed to covey its new goals in meeting the needs of patients around the world.

4. Antidepressants could treat coronavirus, new study suggests

The antidepressant fluvoxamine could treat COVID-19 patients and stop their symptoms from worsening, according to a new study.

5. Pfizer/BioNTech's COVID-19 vaccine shows up to 95% efficacy in final analysis, including in over-65s

Pfizer and BioNTech have backed up their promising interim Phase 3 data showing 90% efficacy for their COVID-19 vaccine candidate with a final analysis of the findings, showing an even higher level of efficacy, and in crucial sub-populations.

6. Bristol Myers Squibb completes $13.1 billion acquisition of MyoKardia

Bristol Myers Squibb has announced that its acquisition of MyoKardia has been completed, with the transaction worth a total of $13.1 billion.

7. FDA approves first at-home coronavirus self-testing kit

The FDA has issued an Emergency Use Authorization for the first coronavirus self-testing kit for use at home that produces rapid results.

8. J&J launches second global COVID-19 vaccine trial, evaluating two-dose regimen

Johnson & Johnson has kicked off a second global Phase 3 trial to assess the safety and efficacy of its COVID-19 vaccine candidate, JNJ-78436735. The company already has the Phase 3 ENSEMBLE study in motion to evaluate a single-dose version of the therapy, with the aim of enrolling up to a total of 60,000 participants.

9. AstraZeneca’s Brilinta reduces stroke and death risk in head and neck artery atherosclerosis patients

AstraZeneca’s Brilinta (ticagrelor) reduced the composite of stroke and death in patients with head and neck artery atherosclerosis who had an acute ischaemic stroke or transient ischaemic attack, according to new clinical trial data.

10. India preparing 100 million doses of AstraZeneca’s COVID-19 vaccine for inoculation programme

India is aiming to have 100 million doses of AstraZeneca’s COVID-19 vaccine ready for an inoculation drive beginning next month.

Conor Kavanagh

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches